Predictive value of microparticle-associated tissue factor activity for permeability glycoprotein-mediated multidrug resistance in cancer

Oncology Letters

Volumn 12, Issue 5, 2016, Pages 3273-3277

  Angelini, Antonio ^a,b   Miscia, Sebastiano ^a,b   Centurione, Maria Antonietta ^c   Di Pietro, Roberta ^a   Centurione, Lucia ^a  

^a Oral and Biotechnological Sciences   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c CNR   (Italy)

Author keywords

Microparticles; Multidrug resistance; P glycoprotein; Tissue factor

Indexed keywords

GLYCOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COAGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HYPERCOAGULABILITY; MALE; MEMBRANE MICROPARTICLE; MIDDLE AGED; MULTIDRUG RESISTANCE; NEOPLASM; OPTICAL DENSITY; PERMEABILITY; PREDICTIVE VALUE; SIGNAL TRANSDUCTION; THROMBOCYTE POOR PLASMA; YOUNG ADULT;

EID: 84990060829     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.5105     Document Type: Article

References (33)

1. Ling V: Multidrug resistance: Molecular mechanism and clinical relevance. Cancer Chemother Pharmacol 40 (Suppl): S3-S8, 1997.
2. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
3. Sauna ZE, Smith MM, Müller M, Kerr KM and Ambudkar SV: The mechanism of action of multigrug-resistance-linked P glycoprotein. JBioenerg Biomembr 33: 481-491, 2001.
4. Gottesmann MM, Fojo T and Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
5. Gillet JP and Gottesman MM: Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596: 47-76, 2010.
6. Higgins CF: Multiple molecular mechanism for multidrug resistance transporters. Nature 446: 749-757, 2007.
7. Ward AB, Szewczyk P, Grimard V, Lee CW, Martinez L, Doshi R, Caya A, Villaluz M, Pardon E, Cregger C, etal: Structures of P glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc Natl Acad Sci USA 110: 13386-13391, 2013.
8. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, etal; American Society of Clinical Oncology Practice: Venous thromboembolism prophilaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. JClin Oncol 31: 2189-2204, 2013.
9. Sørensen HT, Mellemkjaer L, Olsen JH and Baron JA: Prognosis of cancers associated with venous thromboembolism. NEngl JMed 343: 1846-1850, 2000.
10. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM and Melton LJ III: Risk factors for deep vein thrombosis and pulmonary embolism: A population based case-control study. Arch Intern Med 160: 809-815, 2000.
11. Khorana AA, Francis CW, Culakova E, Kuderer NM and Lyman GH: Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110: 2339-2346, 2007.
12. Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer T and Fey MF: Coagulation markers predict survival in cancer patients. Thromb Haemost 88: 745-749, 2002.
13. Callader NS, Varki N and Rao LV: Immunohistochemical identification of tissue factor in solid tumors. Cancer 70: 1194-1201, 1992.
14. Kataoka H, Uchino H, Asada Y, Hatakeyama K, Nabeshima K, Sumivoshi A and Koono M: Analysis of tissue factor and tissue factor pathway inhibitor expression in humanoid colorectal carcinoma cell lines and metastatic sublines to the liver. Int JCancer 72: 878-884, 1997.
15. Uno K, Homma S, Satoh T, Nakanishi K, Abe D, Matsumoto K, Oki A, Tsunoda H, Yamaguchi I, Nagasawa T, etal: Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 96: 290-295, 2007.
16. Antoniou D, Pavlakou G, Stathopoulos GP, Karvdis I, Chondrou E, Papageorgiou C, Dariotaki F, Chaimala D and Veslemes M: Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer 53: 205-210, 2006.
17. Tomimaru Y, Yano M, Takachi K, Kishi K, Miyashiro I, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O and Imaoka S: Correlation between pretreatment d-dimer levels and response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. Dis Esophagus 21: 281-287, 2008.
18. Lwaleed BA and Cooper AJ: Tissue factor expression and multidrug resistance in cancer: Two aspects of a common cellular response to a hostile milieu. Med Hypotheses 55: 470-473, 2000.
19. Piccin A, Murphy WG and Smith OP: Circulating microparticles: Pathophysiology and clinical implications. Blood Rev 21: 157-171, 2007.
20. Hugel B, Martínez MC, Kunzelmann C and Freyssinet JM: Membrane microparticles: Two sides of the coin. Physiology (Bethesda) 20: 22-27, 2005.
21. Haubold K, Rink M, Spath B, Friedrich M, Chun FK, Marx G, Amirkhosravi A, Francis JL, Bokemeyer C, Eifrig B and Langer F: Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost 101: 1147-1155, 2009.
22. Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, Kyrle PA and Welterman A: Tissue factor positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 97: 119-123, 2007.
23. Zwicker JI, Kos CA, Johnston KA, Liebman HA, Furie BC and Furie B: OC-06 tissue factor-bearing microparticles are associated with an increased risk of venous thromboembolic events in cancer patients. Thromb Res 120 (Suppl): S143, 2007.
24. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC and Furie B: Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15: 6830-6840, 2009.
25. Manly DA, Wang J, Glover SL, Kasthuri R, Liebman HA, Key NS and Mackman N: Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 125: 511-512, 2010.
26. Lechner D and Weltermann A: Circulating tissue factor exposing microparticules. Thromb Res 122 (Suppl 1): S42-S54, 2008.
27. Thaler J, Ay C, Mackman N, Bertina RM, Kaider A, Marosi C, Key NS, Barcel DA, Scheithauer W, Kornek G, etal: Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. JThromb Haemost 10: 1363-1370, 2012.
28. Thaler J, Ay C, Mackman N, Metz Schimmerl S, Stift J, Kaider A, Müllauer L, Gnant M, Scheithauer W and Pabinger I: Microparticle-associated tissue factor activity in patients with pancreatic cancer: Correlation with clinicopathological features. Eur J Clin Invest 43: 277-285, 2013.
29. Bharthuar A, Khorana AA, Hutson A, Wang JG, Key NS, Mackman N and Iyer R: Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res 132: 180-184, 2013.
30. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM and Osanto S: Microparticle-associated tissue factor activity: A link between cancer and thrombosis? JThromb Haemost 5: 520-527, 2007.
31. Nitori N, Ino Y, Nakanishi Y, Yamada T, Honda K, Yanagihara K, Kosuge T, Kanai Y, Kitajima M and Hirohashi S: Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 11: 2531-2539, 2005.
32. Angelini A, Di Pietro R, Centurione L, Castellani ML, Conti P, Porreca E and Cuccurullo F: Inhibition of P-glycoprotein-mediated transport by S-adenosylmethionine and cynarin in multidrug-resistant human uterine sarcoma MES-SA/Dx5 cells. JBiol Regul Homeost Agents 26: 495-504, 2012.
33. Angelini A, Centurione L, Sancilio S, Castellani ML, Conti P, Di Ilio C, Porreca E, Cuccurullo F and Di Pietro R: The effect of the plasticizer diethylhexyl phthalate on transport activity and expression of P-glycoprotein in parental and doxo-resistant human sarcoma cell lines. JBiol Regul Homeost Agents 25: 203-211, 2011.